Adam Budzikowski
Clinical Cardiac Electrophysiology · Brooklyn, NYNPI 1790725125
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $187,135 of the $259,011 with a category attached, or 72.2%. 42 manufacturers reported payments, led by Johnson & Johnson at 55.7% of the total. Reporting peaked in 2019 at $60,253 and has fallen 66.2% since, to $20,391 in 2025. Among clinical cardiac electrophysiology clinicians in NY with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 1,131 payments — averaging $229.01 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Johnson & Johnson$144K
- ZOLL Services LLC (a/k/a ZOLL Lifecor Corp)$41K
- Biotronik Inc.$17K
- Abbott$13K
- Scpharmaceuticals Inc.$11K
- Cvrx, Inc.$7K
- plus $25K from 36 others
Across 14 payments — averaging $1189.88 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Cvrx, Inc.$17K
What the payments were for
- Consulting fees$3,4501%
- Speaking & faculty fees$187,13572%
- Travel & lodging$25,88610%
- Food & beverage$41,81716%
- Education$7220%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- XARELTO$142,788
- LifeVest$39,616
- FUROSCIX$10,693
- Barostim Neo System$6,538
- Solia$6,354
- Selectra$4,427
- AVEIR$3,867
- Acticor 7 VR-T DX$3,307
- BioMonitor$2,652
- Arctic Front$1,882
- Edora 8 DR-T$1,849
- Micra$1,704
- Rivacor 7 DR-T$1,691
- Assure WCD$1,594
- AMPLATZER AMULET$1,268
- Allure CRT Pacemaker$1,078
- OPTIMIZER$1,058
- CARDIOMEMS$925
- Claria MRI$793
- Carnation Ambulatory Monitor$669
How this compares
$259,011 in reported general payments places this provider in the 95th percentile of 214 clinical cardiac electrophysiology providers in New York.
See all clinical cardiac electrophysiology providers in New York →
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EntrestoSacubitril/Valsartan | 384 | $506,990 |
| XareltoRivaroxaban | 331 | $426,757 |
| EliquisApixaban | 251 | $299,307 |
| FarxigaDapagliflozin Propanediol | 261 | $280,485 |
| JardianceEmpagliflozin | 180 | $235,502 |
| FuroscixFurosemide | 25 | $158,644 |
| SynjardyEmpagliflozin/Metformin Hcl | 101 | $142,083 |
| MounjaroTirzepatide | 93 | $138,958 |
| MultaqDronedarone Hcl | 68 | $114,778 |
| OzempicSemaglutide | 38 | $47,413 |
| VerquvoVericiguat | 26 | $26,238 |
| Repatha PushtronexEvolocumab | 33 | $25,665 |
| Dofetilide | 38 | $20,340 |
| CorlanorIvabradine Hcl | 19 | $17,405 |
| Amlodipine-Valsartan-HctzAmlodipine/Valsartan/Hcthiazid | 24 | $11,688 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| NovartisEntresto | $446 | $506,990384 claims |
| Johnson & JohnsonXarelto | $144,355 | $426,757331 claims |
| Boehringer IngelheimJardiance, Synjardy | $997 | $377,585281 claims |
| PfizerEliquis | $101 | $299,307251 claims |
| AstraZenecaFarxiga, Brilinta | $490 | $288,904273 claims |
| Scpharmaceuticals Inc.Furoscix | $11,104 | $158,64425 claims |
| Lilly USA, LLCMounjaro | $72 | $138,95893 claims |
| Sanofi-aventis U.S. LLCMultaq | $534 | $114,77868 claims |
| MerckVerquvo | $333 | $26,23826 claims |
| AmgenCorlanor | $75 | $17,40519 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 214 clinical cardiac electrophysiology providers in New York.
Other clinical cardiac electrophysiology in Brooklyn
- Felix YangBrooklyn$407K
- Bharath ReddyBrooklyn$117K
- Gregory CunnBrooklyn$57K
- Vivek ReddyNew York$14.9M
- Jacob KoruthNew York$3.7M
- Srinivas DukkipatiNew York$2.7M
- Amir AhmadiNew York$789K
- Larry ChinitzNew York$448K
- James IpNew York$347K
- Stavros MountantonakisManhasset$321K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.